Clinical Evaluation of the Effects of EpiCor on Digestive Comfort

NCT ID: NCT03051399

Last Updated: 2017-02-14

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 80 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-07-06
• Study Completion Date: 2016-11-30

Brief Summary

Previous in vitro studies suggest that EpiCor is well fermented in the colon and has prebiotic potential. The repeated long-term administration of low doses of EpiCor in the Simulator of the Human Intestinal Microbial Ecosystem (SHIME) has shown that this product is able to induce gradual changes in the colonic environment by: i) being selectively fermented, leading to butyrate increase in the colon; ii) stimulating Lactobacilli growth in the lumen and adherence to the mucosal surface, and iii) decreasing potential pathogens. In addition, the fermentation-derived metabolites produced in the colon were shown to potentially benefit the host by decreasing cytokine levels in vitro. As a result, the investigators hypothesize that EpiCor may help to improve bowel function and generally contribute to enhanced gut health. Therefore, this pilot study is intended to assess the effects of long-term administration of EpiCor on a population with mild symptoms of intestinal dysfunction.

The primary objective of this exploratory pilot study is to assess the effect of long term administration of EpiCor on bowel function and gastrointestinal well-being, by means of validated questionnaires.

This study has 4 secondary objectives: 1) The first secondary objective of this study is to assess the protective effects of EpiCor on intestinal barrier function, by performing a gut sugar permeability test in combination with indomethacin challenge; 2) The second secondary objective is to assess the effects of EpiCor on intestinal barrier function, by measuring blood Zonulin and endotoxin levels in combination with indomethacin challenge; 3) The third secondary objective of this study is to assess the prebiotic properties of EpiCor by collecting fecal samples. The microbial community composition, lactate and SCFA profiles and proteolytic activity markers in feces will be determined. Proteolytic activity markers will also be measured in urine samples; 4) The fourth secondary objective of this study is to assess the effects of EpiCor on local and systemic immune system performance by measuring secretory IgA levels in feces and cytokines in blood.

Detailed Description

Study design:

In this project the effects of repeated daily intake of EpiCor will be investigated. The design conforms to a randomized, double-blind, placebo-controlled parallel design. In total, there will be two study groups: one group receiving placebo treatment (maltodextrin 500mg daily dose, single serving) and one group receiving EpiCor (500mg daily dose, single serving). Each eligible individual will participate in one of two experimental arms of the study for minimum 6 weeks. Before randomization, there will be a run-in period of 2 weeks in which the participants are prohibited from consuming products containing pre- or probiotics.

Study population:

Healthy human male/female volunteers with mild symptoms of intestinal dysfunction. Subject recruitment will start after ethics committee approval of the study. After obtaining signed informed consent and confirmation of eligibility, each subject will have 4 test days at the study site. Each subject will participate during approximately 8 to 10 weeks in this study. In total, 80 subjects will complete the study (40 subjects in each trial arm). For any patient withdrawn from the study, an alternative candidate will be selected in order to ultimately meet the required number of subjects. The total study duration will be approximately 20 weeks.

Study endpoints:

The primary endpoint for this study is the effect of long-term administration of EpiCor on digestive comfort. Digestive comfort will be assessed by means of evaluation (questionnaires) of i) Gastrointestinal (GI) symptoms (bloating/distension; passage of gas; GI rumbling; feeling of fullness and abdominal discomfort) and ii) frequency/consistency of stools. General gastrointestinal well-being and improvement of quality of life will also be evaluated by means of questionnaires.

Secondary endpoints are i) the protective effects of EpiCor on gut barrier function after indomethacin challenge (assessed by a sugar test in urine samples), ii) the effects of EpiCor on gut barrier function after indomethacin challenge (assessed by quantification of Zonulin in blood), iii) evaluation of EpiCor's prebiotic properties (assessed by microbiota-related analyses on fecal contents) and iv) the effect of EpiCor on local and systemic immune system performance (assessed by measuring secretory (s)IgA levels in feces and cytokines in blood).

Study product:

EpiCor (Embria Health Sciences) is the brand name for a substance consisting of a dried yeast fermentate made using Saccharomyces cerevisiae fermentation. All published human studies on EpiCor used a daily dosage of 500mg for adults. Moreover, this is the commercially recommended daily dosage, and will also be used in this study. The placebo used in this study is Globe maltodextrin 10 (CPIngredientes, Mexico). This commercially available product is a mixture of dextrose, maltose, oligo and polysaccharides obtained by partial enzymatic hydrolysis of corn starch. Maltodextrin is the most commonly used placebo in dietary studies evaluating gut microbiota and intestinal well-being. It is easily digestible and rapidly absorbed as glucose and has no effect on colonic fermentation.

EpiCor and placebo will be provided in capsules. The capsules used in this study will be the Coni-Snap® capsules, two-piece hard gelatin capsules (Capsugel, Mexico).

Blinding procedures:

Blinding is ensured by the fact that both capsules are opaque and have an identical appearance and are packaged in identical bottles by Embria Health Sciences. A ProDigest staff member not participating in the study will label all bottles and assign them to each subject in accordance to the randomization list. The capsules will be packed in identical bottles. Each bottle will contain a weekly dose (=7 capsules per bottle).

The participants will be asked to orally ingest one capsule per day, in combination with 200mL water. The capsules will consist of 500mg EpiCor® or 500mg maltodextrin. To ensure a standardized intake, participants will be asked to take the capsule every morning before breakfast. No interactions with food are reported, and so participants may proceed with their usual food habits. Participants will be asked to hand in the empty bottles; these will be used to measure compliance.

The products are to be stored at room temperature in dry conditions in the closed bottles (preferably between 15 and 25 °C) for the duration of the study.

Conditions

Constipation; Gastrointestinal Discomfort

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo

Maltodextrin, 500 mg/day, single serving

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DIETARY_SUPPLEMENT

The participants will be asked to orally ingest one capsule per day (500 mg maltodextrin, single serving), in combination with 200mL water.

EpiCor

EpiCor, 500 mg/day, single serving

Group Type: ACTIVE_COMPARATOR

EpiCor

Intervention Type: DIETARY_SUPPLEMENT

The participants will be asked to orally ingest one capsule per day (500 mg EpiCor, single serving), in combination with 200mL water.

Interventions

Placebo

The participants will be asked to orally ingest one capsule per day (500 mg maltodextrin, single serving), in combination with 200mL water.

Intervention Type: DIETARY_SUPPLEMENT

EpiCor

The participants will be asked to orally ingest one capsule per day (500 mg EpiCor, single serving), in combination with 200mL water.

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• Based on medical history, healthy volunteers without clinical diagnosed diseases with relevant effect on gastrointestinal system or on visceral motility.
• At the moment of initial inclusion subjects will be recruited for run-in phase if having reported:

1. Gastrointestinal (GI) symptoms of at least 5 points for the previous 3 months based on self-assessment, or

2. Reduced bowel movements defined as an average of >1 and ≤5 stools per week for the previous 3 months based on self assessment.

• For at least 50 subjects, an additional inclusion criterion will have to be met based on the daily recorded GI symptoms: at the end of the run-in phase, a score of > or = 5 for GI symptoms should be obtained based on the average calculated from the daily scores of the 2-week run-in period. For the remaining 30 subjects, no additional inclusion criterion will be required.
• Age > or = 18 and < or = 70 years.
• Male or female.
• No pregnancy in the last 6 months.
• Body mass index (BMI) 18-35 kg/m2 (BMI = weight (kg) divided by length (m) squared).
• Consistently stable body weight (± 5%) for at least 6 months and no weight reduction treatment during the study period.
• Written consent to participate in the study.
• Able and willing to follow the study protocol procedures

Exclusion Criteria

• History of severe gastrointestinal/hepatic, hematological/immunologic, metabolic/nutritional disorders, endocrine disorders, celiac disease, type I diabetes mellitus, major surgery and/or laboratory assessments which might limit participation in or completion of study period. Participants having other diseases will be considered or not for randomization after careful evaluation by the principle investigator.
• Use of medication, including vitamin supplementation, except oral contraceptives, within 14 days prior to first dosing. Some medication may be used, if it is considered not to influence gastrointestinal function and motility, upon mutual agreement of the investigator and sponsor.

a. In particular, the use of any non-steroidal inflammatory drugs (NSAIDs) starting 14 days prior to first dosing is prohibited.

• Systemic antibiotics treatment within 60 days prior to first dosing.
• Intake of laxatives or anti-diarrheic drugs within 14 days prior to first dosing.
• Change of dietary habits within the 4 weeks prior to screening (for instance start of a diet rich in fibers).
• Participants anticipating a change in lifestyle or physical activity levels during the study.
• Administration of investigational drugs or participation in any scientific intervention study which may interfere with this study (to be decided by the principle investigator), in the 60 days prior to first dosing.
• Major abdominal surgery interfering with gastrointestinal function (uncomplicated appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon judgment of the principle investigator).
• Known pregnancy or lactation (checked by a pregnancy test before start of study).
• Dependence on illegal drugs or alcohol.
• Smoking within the last 3 months.
• Blood donation within 1 month before study period.
• Prohibited use of pro-, pre- or synbiotics from 30 days before first dosing and during the study period. A list with forbidden products will be provided.
• Hepatitis C-, B- or HIV-positive (to be tested before start of study).
• History of any major side effects towards intake of pro- or prebiotic supplements of any kind.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

University Ghent

OTHER

Sponsor Role: collaborator

Maastricht University

OTHER

Sponsor Role: collaborator

Embria Health Sciences

UNKNOWN

Sponsor Role: collaborator

ProDigest

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Iris Pinheiro, PhD

Role: PRINCIPAL_INVESTIGATOR

ProDigest

References

Pinheiro I, Robinson L, Verhelst A, Marzorati M, Winkens B, den Abbeele PV, Possemiers S. A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial. BMC Complement Altern Med. 2017 Sep 4;17(1):441. doi: 10.1186/s12906-017-1948-0.

Reference Type: DERIVED

PMID: 28870194 (View on PubMed)

Other Identifiers

15-PDEMB1/DRUG15-MB1

Identifier Type: -

Identifier Source: org_study_id